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Background: Mechanical valves and bioprostheses are widely used for aortic valve replacement. Though
previous randomised studies indicate that there is no important difference in outcome after implantation
with either type of valve, knowledge of outcomes after aortic valve replacement is incomplete.
Objective: To predict age and sex specific outcomes of patients after aortic valve replacement with bileaflet
mechanical valves and stented porcine bioprostheses, and to provide evidence based support for the
choice of prosthesis.
Methods: Meta-analysis of published results of primary aortic valve replacement with bileaflet mechanical
prostheses (nine reports, 4274 patients, and 25 726 patient-years) and stented porcine bioprostheses (13
reports, 9007 patients, and 54 151 patient-years) was used to estimate the annual risks of postoperative
valve related events and their outcomes. These estimates were entered into a microsimulation model, which
was employed to calculate age and sex specific outcomes after aortic valve replacement.
Results: Life expectancy (LE) and event-free life expectancy (EFLE) for a 65 year old man after implantation
with a mechanical valve or a bioprosthesis were 10.4 and 10.7 years and 7.7 and 8.4 years, respectively.
The lifetime risk of at least one valve related event for a mechanical valve was 48%, and for a
bioprosthesis, 44%. For LE and EFLE, the age crossover point between the two valve types was 59 and 60
years, respectively.
Conclusions: Meta-analysis based microsimulation provides insight into the long term outcome after aortic
valve replacement and suggests that the currently recommended age threshold for implanting a
bioprosthesis could be lowered further.
M
echanical valves and bioprostheses are common valve
types used in aortic valve replacement.1 2 However,
both are known to have inherent advantages and
disadvantages. Mechanical valves, for example, offer long
term durability but are thrombogenic, necessitating life long
anticoagulation that carries an increased risk of haemor-
rhage. In contrast, bioprostheses are less thrombogenic,
which in most patients obviates the need for long term
anticoagulant agents; however, their propensity to undergo
structural valvar deterioration (SVD) limits their durability.3
The risk of haemorrhage with mechanical valves and the risk
of SVD in bioprostheses are age dependent, the first
increasing and the latter decreasing with advancing age.4 5
Consequently, the choice between a mechanical valve and a
bioprosthesis for a given patient undergoing aortic valve
replacement involves striking a balance between the risks
and benefits of each valve type. Thus a knowledge of the
outcomes after aortic valve replacement for each type of valve
could assist surgeons in their choice of valve.
Microsimulation and associated simulation techniques are
capable of providing insight into outcomes after aortic valve
replacement. We therefore combined meta-analyses of
several clinical studies with microsimulation to study the
outcomes of patients after aortic valve replacement with
bileaflet mechanical valves and stented porcine bioprosth-
eses.
METHODS
Meta-analysis
We conducted a literature search of the Medline database
using the PubMed search interface to identify reports which
considered the following valves: St Jude Medical (SJM)
bileaflet valves, ‘‘standard’’ and ‘‘haemodynamic plus’’
models (St Jude Medical Inc, Minneapolis, Minnesota,
USA); Carpentier-Edwards ‘‘standard’’ and ‘‘supra-annular’’
valves (Baxter Healthcare Corporation, Chicago, Illinois,
USA) or Hancock ‘‘standard,’’ ‘‘modified orifice,’’ and
‘‘Hancock II’’ valves (Medtronic Inc, Minneapolis,
Minnesota, USA). The MeSH terms in combination with
the text words ‘‘St Jude’’ for the mechanical valves and
‘‘stented,’’ ‘‘Hancock,’’ ‘‘Carpentier-Edwards,’’ or ‘‘modified
orifice’’ for the bioprostheses, respectively, were used for the
search. The search was limited to the period January 1990 to
October 2001 and to the English language. The title and
abstracts of the studies obtained were screened for those that
examined outcomes following aortic valve replacement.
References in these reports were cross checked for other
relevant studies. This resulted in 76 published reports for
mechanical valves and 68 for bioprostheses. The following
criteria for each valve type were then stipulated in order to
obtain homogeneous groups of studies:
N Valves 19–33 mm in size, not focusing on a particular size
or range.
N Patients .15 years of age; mean age of the study
populations, > 50 years.
N Predominantly first time aortic valve replacement (. 90%).
N Aortic valve replacement with or without concomitant
coronary artery bypass grafting (CABG) or any other valve
repair procedure, but excluding other valve replacements.
Abbreviations: EFLE, event-free life expectancy; SVD, structural valvar
deterioration; UKHVR, United Kingdom Heart Valve Registry
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N Valve related events ascertained according to standard
definitions published in 19886 and 1996.7
N For mechanical valves: an international normalised ratio
(INR) between 1.8 and 4.5.
Studies that had overlapping patient populations were
excluded. Finally, nine reports on St Jude Medical mechan-
ical valves4 8–15 and 13 reports on stented porcine bioprosth-
eses8 16–27 were selected. Heterogeneity in the selected
publications was investigated by sensitivity analysis.
Morbidity and mortality data on valve related events were
obtained from these selected reports (see the appendix).
Microsimulation
The data on valve related events obtained from the meta-
analysis were entered into a microsimulation model. This is a
computer application that simulates the remaining lifetime of
a given patient, taking into account all morbidity and
mortality events and sequences of events that the patient
might experience after aortic valve replacement. The basic
structure of the model is shown in fig 1.
The microsimulation model assumes that after aortic valve
replacement a patient follows a course over time that can be
adequately characterised by various discrete states. After
aortic valve replacement, the patient can either die as a result
of the operation, or can remain alive. The mortality of a
patient who remains alive after aortic valve replacement is
greater than that of a matched individual in the general
population. This extra or excess mortality in the patient
compared with a matched person in the general population
reflects valve related events and ‘‘additional mortality’’
associated with the underlying valve pathology, left ventri-
cular function, and the valve replacement procedure per se.28
The model incorporates the mortality experience of the
general population, called the background mortality, by
means of life tables of the relevant population (for example,
American men). Mortality from valve related events is
incorporated using the data obtained from the meta-analysis.
The ‘‘additional mortality’’ experienced by patients having
aortic valve replacement is not clearly defined or estimated at
present. Thus we estimated age and sex specific hazard ratios
to represent the effect of the ‘‘additional mortality’’. This was
done by approximating age and sex specific survival curves
produced by the model—which contained the background
mortality and the mortality from valve related events—to the
corresponding empirical curves obtained from published
reports,20 which contained all three components of mortality.
Hazard ratios of 2.9, 1.8, 1.2, and 0.8 were estimated for male
patients aged 45, 55, 65, and 75 years, respectively.
The model calculates patient outcomes by superimposing
the morbidity and mortality estimates of valve related events
on the background mortality and additional mortality
incorporated in the model. Ten thousand simulations of a
given patient create a ‘‘virtual’’ patient population—that is, a
cohort of patients with identical characteristics but with all
possible outcomes after aortic valve replacement. From this
large cohort of identical patients, the model calculates the
average life expectancies and lifetime risks of valve related
events for that given patient. A detailed account of the
microsimulation structure and methodology has been sup-
plied previously.29
Validation
To assess the agreement between age and sex specific model
calculations and the corresponding true life experience of
patients with aortic valve replacements, the results of the
model were compared with the long term outcomes of
patients in large datasets from Portland, Oregon, USA30 and
the United Kingdom Heart Valve Registry (UKHVR), UK.31
The Portland dataset, from St Vincent Heart Institute,
Portland, Oregon, contains 30 years of follow up data on
patients who underwent aortic valve replacement with the
Starr-Edwards mechanical prosthesis and the Carpentier-
Edwards ‘‘standard’’ bioprosthesis, and includes data on age,
sex, and CABG. The UKHVR, which is based at the
Hammersmith Hospital, London, is a computerised database
that prospectively collects data on heart valve replacement
surgery carried out in all cardiac centres throughout the UK.
These include certain preoperative, implant, and postopera-
tive data matched against individual patient demo-
graphics. All patients are followed up through the national
agencies responsible for registering all deaths of UK
nationals. The 15 year follow up data on bileaflet mechanical
valves and stented porcine bioprostheses were used for the
validation.
Figure 1 Basic structure of the microsimulation model.
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Sensitivity analysis
A one way sensitivity analysis was conducted to investigate
the effect of uncertainty in parameter estimates. Variation in
the estimates of the valve related events by their 95%
confidence intervals resulted in very small variations in the
life expectancies. Hence we defined larger ranges by
increasing and decreasing the baseline estimates by 25%.
For SVD, the median time to SVD was varied by 10%.
RESULTS
Meta-analysis
The nine selected reports on St Jude Medical mechanical
valves comprised 4274 patients and a total follow up of
25 726 patient-years. The 13 reports on stented porcine
bioprostheses included 9007 valve recipients and 54 151
patient-years of follow up. The mean age was 59.1 and 65.4
years, respectively. Approximately 65% of patients in both
groups were male (tables 1 and 2). The incidence of valve
related events and their outcomes are given in table 3. The
most frequent events were thromboembolism and haemor-
rhage in the mechanical valves, and thromboembolism and
SVD in the bioprostheses. The incidence of endocarditis was
3.9% and 3.2% during the initial six months after implanta-
tion of mechanical and bioprostheses, respectively.
Microsimulation
The microsimulation model calculates total life expectancy
and event-free life expectancy (EFLE) following aortic valve
replacement with mechanical valves and bioprostheses for
patients of either sex and of different ages. We give the
results for male patients. For a 65 year old man, for example,
life expectancy was 10.4 and 10.7 years and EFLE was 7.7 and
8.4 years, respectively, after implantation with a mechanical
valve and a bioprosthesis. Comparisons of life expectancy and
EFLE are shown in fig 2. When considering life expectancy
and EFLE, the age crossover points between the two valve
types were 59 and 60 years, respectively.
The lifetime risks of the more common valve related events
are depicted in fig 3. As seen in fig 3A, the lifetime risk of
SVD following a bioprosthesis reduces with advancing age
at implantation, and is about 10% for a 75 year old patient.
For the mechanical valves, the decreasing risk of throm-
boembolism with advancing age at implantation, concomi-
tant on a decreasing life expectancy, is opposed by an
increasing risk of haemorrhage (fig 3B). When considering
the lifetime risk of experiencing at least one valve related
event, the age crossover point for aortic valve replacement
was 63 years.
Validation
The results from our model for male patients of different
ages and for both valve types were compared with the
corresponding long term survival data from Portland,
Oregon.30 The overall agreement was favourable (fig 4,
panels A and B). Applying the UK background mortality
estimates, we also compared model outputs with the 15 year
experience of the UKHVR.31 Interestingly, the UK patients
appeared to have a better survival. For example, when the
model output for a 62 year old man who received a
bioprosthesis was compared with a similar group of 60–65
year old men in the UKHVR, the 15 year survival calculated
by the model was 36%, as compared with 47% (40–53%) in
the UKHVR.
Sensitivity analysis
The EFLE for a 60 year old man and the corresponding age
crossover point between the two valve types, for extreme
values of some selected valve related events, are given in
table 4. A change in the risk of SVD was shown to have the
largest influence on EFLE and the age crossover point.
Table 1 Characteristics of the nine reports selected for the meta-analysis of St Jude
Medical aortic valve prostheses
Reference No
Total8 9 10 11 4 12 13 14 15
Type of study RS RS RS PS RS PS RS RS RS
Patients (n) 412 351 694 418 666 204 178 773 578 4274
% Male 59 72* 62 70 60 46* 63 69 , 64
Mean age
(years)
62 54 58 55 66 52* 51 57 59* 59
Follow up
(patient-years)
1800* 1640 4502 2376 3881 1969 699 6419 2441 25 726
% Concomitant
CABG
42 22 24 27 50 , 7 9* 17 30
*Approximate figures.
,Data not available.
CABG, coronary artery bypass graft; PS, prospective study; RS, retrospective study.
Table 2 Characteristics of the 13 reports selected for the meta-analysis of the stented porcine bioprostheses
Reference No
Total16 17 18 19 20 21 22 23 8 24 25 26 27
Type of study PS , PS RS RS PS RS RS RS RS RS RS ,
Patients (n) 843 395 1108 165 1594 670 136 281 429 573 1823 561 429 9007
% Male 58 62 49 70 71 75 85 62 72 , , 70 73 65
Mean age (years) 69 66 74 67 60 65 50 75 64 59 69 72 64 65
Follow up (patient-years) 5093 1264 4735 551 10 212 4813 1496 937 3000 5187 12640 1792 2431 54 151
% Concomitant CABG 43 31 , 19 34 43 7 , 35 , 42 39 34 37
*Approximate figures.
,Data not available.
CABG, coronary artery bypass graft; PS, prospective; RS, retrospective.
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DISCUSSION
Simulation methods are widely used in operations research
and management science.32 A well known example of a
simulation program is the flight simulator in the aviation
industry. Although not commonly used in clinical medicine,
simulation models have been used previously to determine
the prognosis of patients after aortic valve replacement.33 34
We have designed a microsimulation model which calculates
the outcomes of patients after aortic valve replacement.
Compared with standard statistical techniques, the added
value of microsimulation is that it allows modelling of the
complex outcome pathways resulting from the many
simultaneous risks, and provides detailed insight into the
outcomes of patients following valve replacement, deducible
to the individual patient. The structure of the model
incorporates a schematic representation of the lives of
patients with aortic valve replacement (fig 1) and, in
principle, the model can be applied to any valve type. For
this analysis, data from meta-analysis of published reports
were incorporated into the model to predict the outcomes of
patients after aortic valve replacement with bileaflet mechan-
ical valves and stented porcine bioprostheses, respectively.
Ideally for simulation methodology, a comprehensive
dataset should be available. This dataset should contain
detailed information on a wide range of patients, including
data on all valve related events and long term follow up.
However, such a database is hard to assimilate and is not
available at present. Hence we pooled empirical data and
quantified estimates required to parameterise the model. An
advantage of pooling data was that it represented the
experience of many institutions and countries and thereby
enhanced the generalisability of the results. We selected the
St Jude Medical valve, a bileaflet low profile prosthesis, to
represent the mechanical valves. It is one of the most
commonly implanted mechanical prostheses at present.1 We
further selected five types of stented porcine bioprosthesis,
both first and second generation, to represent the bioprosth-
eses. No overt differences in the performance of these valves
have been documented in published reports.35–38
Table 3 Pooled incidence of valve related events and their outcomes after aortic valve replacement with a mechanical valve
and a bioprosthesis
Valve related events
Events (n) LOR (per 100 patient-years) Outcome, death rate Reoperation rate
Mech Bio Mech Bio Mech Bio Mech Bio
Valve thrombosis 39 2 0.16 0.01 0.22 0.67 0.63 0.33
Thromboembolism 419 717 1.6 1.3 0.17 0.18 0 0.01
Haemorrhage 419 189 1.6* 0.4 0.14 0.2 0 0
Endocarditis 89 240 3.9/0.66 3.2/0.48 0.43 0.36 0.53 0.5
NSD 70 91 0.29 0.3 0.04 0 0.37 0.43
SVD 0 469 0 ` 0 0.12 0 0.75
*A Gompertz model was constructed.
A two period exponential model was constructed for risk during and after the first six months after implantation.
`A Weibull model was constructed incorporating age dependency.
Bio, bioprosthesis; LOR, linearised occurrence rate (or hazard); Mech, mechanical valve; NSD, non-structural dysfunction; SVD, structural valvar deterioration.
Figure 2 Comparison of life expectancy and event-free life expectancy
in men after aortic valve replacement with mechanical valves and
bioprostheses.
Figure 3 (A) Lifetime risk of thromboembolism, haemorrhage, and
structural valvar deterioration following aortic valve replacement with
bioprostheses in men of different ages. (B) Lifetime risk of
thromboembolism and haemorrhage following aortic valve replacement
with mechanical valves in men of different ages.
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The actuarial method and the Kaplan-Meier analysis have
been used in many studies to estimate the survival of patients
after aortic valve replacement. However, when applied to
non-fatal complications such as SVD, the risk described is
what patients would experience provided they were immor-
tal, and answers the hypothetical question ‘‘what is the risk
of the event if no patient ever died?’’. A more relevant
estimate is the actual percentage of patients who will
experience an event before they die. Estimation of the
cumulative incidence—termed ‘‘actual’’ analysis in the
cardiac literature—has recently gained interest.39 This
method modifies the survival estimate to exclude future
events attributed to already dead patients, and answers the
question ‘‘what is the lifetime risk of the event?’’. The
microsimulation model provides estimates of the lifetime risk
of valve related events (fig 3, panels A and B). Thus, for
example, a 65 year old man would have a 48% risk of
experiencing at least one valve related event if he had a
mechanical valve replacement, compared with 44% if he had
a bioprosthesis. The age crossover point was 63 years. As
depicted in fig 3, panels A and B, the crossover point in
overall valve complications follows the increasing risk of
haemorrhage with advancing age of implantation in mechan-
ical valves, balanced against the decreasing risk of SVD with
advancing age in bioprostheses.
The model predicted a life expectancy of 10.4 and 10.8
years, respectively, for a 65 year old man following
implantation with a mechanical valve and a stented
bioprosthesis. Considering life expectancy, the age crossover
point between either valve type was 59 years. This result
concurs well with the results of Birkmeyer and colleagues,33
who used a Markov state transition model to simulate the
prognosis of patients with aortic valve replacement. They
obtained a crossover point of 60 years. The microsimulation
model also calculates the EFLE after aortic valve replacement.
For the 65 year old male patient, for example, the model
predicted an EFLE of 7.7 and 8.4 years, respectively, for
mechanical valves and bioprostheses. Considering EFLE, the
age crossover point between either valve type was 60 years.
Results from previous randomised studies40 41 and another
long term prospective study4 indicate that there is no
significant difference in outcome after implantation with
mechanical valves and bioprostheses. The American College
of Cardiology and the American Heart Association guidelines3
recommend a bioprosthesis for patients > 65 years of age
who do not have risk factors for thromboembolism, based on
the reduced risk of SVD and the increasing risk of
haemorrhage above this age. Our results suggest that,
contrary to current recommendation, a bioprosthesis can be
considered for patients under 65 years of age. New strategies
being developed to retard mineralisation of xenograft
valves2—with, one hopes, a concomitant reduction in SVD
risk—would further support reduction of the 65 year old
threshold. Nevertheless, patient related factors including
Figure 4 (A) Comparison of microsimulation model output and corresponding Portland data for 50, 60, and 70 year old men after aortic valve
replacement with mechanical valves. (B) Comparison of microsimulation model output and corresponding Portland data for 50, 60, and 70 year old
men after aortic valve replacement with bioprostheses.
Table 4 Summary of one way sensitivity analysis
Variable (valve type)
Baseline
estimate
Plausible range* Event-free life expectancy (years) Age crossover point`
Favourable Unfavourable Favourable Unfavourable Favourable Unfavourable
Thromboembolism (mech) 1.6 1.2 2 9.1 8.6 62 58
Thromboembolism (bio) 1.3 1 1.6 9.1 8.7 59 61
Haemorrhage (mech)1 1.3 1 1.7 9.2 8.5 62 58
Endocarditis (mech) 0.7 0.5 0.9 9 8.7 61 59
SVD (bio) 16 years 17.6 years 14.4 years 9.2 8.5 57 63
*The plausible range was defined by increasing or decreasing the baseline estimates for thromboembolism, haemorrhage, and endocarditis by 25%. For SVD, the
median time to SVD was varied by 10%.
The event-free life expectancy (EFLE) calculated by the model was 8.9 years for a 60 year old man with baseline estimates.
`The age crossover point between mechanical valves and bioprostheses was 60 years for EFLE at baseline analysis.
1Data from another study5 were used to model haemorrhage in mechanical valves. The baseline risk was varied for this analysis.
bio, bioprosthesis; mech, mechanical valve; SVD, structural valvar deterioration.
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individual hazards for valve related events (for example,
increased risk of bleeding), patient preference, type of
surgery, and health care delivery factors also need to be
considered in the decision making process for valve choice in
the individual patient.42 The long term results for mechanical
valves and bioprostheses, calculated using our model, agreed
with the corresponding long term follow up data from
Portland, Oergon30 (fig 4, panels A and B). However, for most
age groups, the British patients31 appeared to have a some-
what better survival than the model results and the American
patients. The smaller number of patients in the UK data
during the latter part of follow up might account for this
discrepancy. If systematically different criteria (New York
Heart Association (NYHA) class, timing of surgery, and so
on) were used in the selection of patients in the UK as
compared with the USA, the ‘‘additional mortality’’ (see
appendix) of the British patients could differ from their
counterparts in the USA. The ‘‘additional mortality’’ inherent
in patients with aortic valve replacement is incorporated into
the model by means of age specific hazard ratios, and hence
different hazard ratios may be required to model the UK
patients.
Limitations of the model included certain structural
adjustments made with respect to the valve related events.
For example, valve thrombosis, thromboembolism, and non-
structural dysfunction was assumed to carry constant
hazards. The risk of endocarditis was assumed to be constant
during the early and late phases. These hazards may in fact
be time and age dependent, and hence further knowledge is
necessary to address these assumptions. Survival after aortic
valve replacement has also been shown to depend on
preoperative cardiac rhythm, the type of valve lesion, con-
comitant CABG, and NYHA functional status.43 Although the
model incorporates these factors non-specifically by means of
hazard ratios, it cannot determine the individual influence of
these factors on overall survival. At present, the model can
only predict outcome for an average risk profile. However, we
are currently incorporating CABG into the model. Ultimately,
we envisage the introduction of a user friendly microsimula-
tion model on the internet, which could be used as a bedside
tool by the cardiologist or surgeon. This microsimulation
methodology could also find application in other fields of
medicine.
Conclusions
We have described the use of microsimulation to provide
insight into age and sex specific long term outcomes after
aortic valve replacement. We suggest that the currently
recommended age threshold for implanting a bioprosthesis
could be lowered further.
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APPENDIX
Input microsimulation model
VALVE RELATED EVENTS
The annual hazards of valve thrombosis, thromboembolism,
and non-structural dysfunction (NSD) were considered to be
constant over time. Weighted pooling was used to obtain
combined estimates of the linearised annual occurrence rates
(LOR) for these events. The estimates for endocarditis, and
for SVD in bioprostheses, were obtained by pooling the
respective freedom-from-event curves.44 The risk of endocar-
ditis was assumed to take two phases of constant hazard,
with the hazard during the first six months greater than the
subsequent period. Therefore, we fitted two-period exponen-
tial models to the pooled freedom-from-endocarditis curves
of the two valve types.
The risk of SVD in bioprostheses depends on the time
elapsed since valve replacement and the age of the patient at
implantation. This relation is well described by a Weibull
model.45 The Weibull model is a generalisation of the
exponential distribution, which incorporates an additional
shape parameter. The shape parameter reflects the changing
risk of SVD over time. We estimated the shape parameter
from the pooled freedom from SVD curve and calculated the
age effect from another selected study.20 The formula for
freedom from SVD is:
S(t)= e2(t/s)‘b
where S(t) indicates the probability of remaining free from
SVD at time t, while s and b denote the scale and shape
parameters of the model. The value of s depends on age:
s=e2.21+0.0112 * age while b=3.35.
With these parameters, the median time to SVD was 15.1,
16.8, and 18.8 years, respectively, for 55, 65, and 75 year old
male patients. As per meta-analysis, a zero risk of SVD was
assigned for the mechanical valves.
Incorporating data from a previous study,5 haemorrhage
after aortic valve replacement with mechanical valves was
modelled using the Gompertz distribution, which takes into
account the exponentially increasing hazard of that event
with patient age. Mortality and reoperation rates associated
with individual valve related events was also estimated
(table 3).
OPERATIVE MORTALITY
Operative mortality was estimated at 1.5% for a 40 year old
male patient, increasing with odds ratios of 1.022 per year
and 1.7 with every reoperation.
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he follow electronic only articles are published in
conjunction with this issue of Heart.
Fatal fulminant myocarditis caused by disseminated
mucormycosis
A Basti, S Taylor, M Tschopp, J Sztajzel
Acute fulminant myocarditis is a critical clinical condition
with sudden onset of severe congestive heart failure followed
by severe haemodynamic deterioration. Instituting early left
ventricular support may improve outcome and result in better
long term survival. The case of an immunocompromised
patient who developed acute fulminant myocarditis in the
setting of disseminated mucormycosis is presented.
(Heart 2004;90:e60) www.heartjnl.com/cgi/content/full/90/
10/e60
Intravascular ultrasound findings of coronary wall
morphology in a patient with pseudoxanthoma
elasticum
K Miwa, T Higashikata, H Mabuchi
Pseudoxanthoma elasticum (PXE) is an inherited disorder
characterised by progressive calcification of the elastic fibres
in the skin, eye, and cardiovascular system. Recently,
mutations in the ATP binding cassette transporter gene
(ABCC6) were identified as cause of this disease. Although
patients with PXE often have coronary artery disease, little is
known about the process and the mechanism of coronary
artery disease in PXE. In this report, intravascular ultrasound
(IVUS) imaging was performed in a female patient with PXE
seven years after the onset of skin lesion to assess the
coronary wall morphology in detail. IVUS showed a unique
five layer appearance without acoustic shadowing along the
vessel wall observed in the angiographically normal portion.
These findings may reflect the earlier stage of coronary artery
disease caused by PXE before calcification of the internal
elastic laminae.
(Heart 2004;90:e61) www.heartjnl.com/cgi/content/full/90/
10/e61
Percutaneous device closure of a pseudoaneurysm of
the left ventricular wall
P Clift, S Thorne, J de Giovanni
The percutaneous device closure of a left ventricular
pseudoaneurysm is described in a 60 year old man with a
history of myocardial infarction complicated by ventricular
tachycardia and left ventricular aneurysm treated by coro-
nary artery bypass grafting and aneursymectomy with
ventricular tachycardia ablation. He subsequently developed
a vast pseudoaneurysm of the left ventricle with New York
Heart Association functional class II heart failure symptoms.
The selection of the approach and type of device used to close
the neck of the pseudoaneurysm are discussed.
(Heart 2004;90:e62) www.heartjnl.com/cgi/content/full/90/
10/e62
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